CytoDyn Inc.
CYDY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$382.07M
Close$
$-0.02
109.4% downside
Current Fair Value
109.4% downsideOvervalued by 109.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $382.07 Million |
|---|---|
| Enterprise Value | $397.50 Million |
| Earnings per Share | $-0.03 |
| Beta | 1.24 |
| Outstanding Shares | 1,382,223,000 |
Return
| Return on Equity | 52.04% |
|---|---|
| Return on Assets | -408.61% |
| Return on Invested Capital | 103.87% |
Valuation & Multiples
| P/E Ratio | -5.87 |
|---|---|
| PEG | -2.26 |
| Price to Sales | - |
| Price to Book Ratio | -0.22 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -9.63 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | -0.25 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 15, 2026
EPS Estimate
$-0.05
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
January 14, 2027
EPS Estimate
$-0.05
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 0.01% |
|---|---|
| Total Invested | $35,217▼ 59.58% |
| Investors Holding | 6▼ 3.00% |
About CytoDyn Inc.
14 employees
CEO: Jacob Lalezari
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humaniz...